Results 31 to 40 of about 1,753 (162)

Selective IL-13 inhibitors for the treatment of atopic dermatitis

Drugs in Context, 2021
Background: Atopic dermatitis (AD) is one of the most common chronic inflammatory skin diseases worldwide. AD pathogenesis is multifactorial, involving environmental and genetic factors.
Francisca Gonçalves, Egídio Freitas, Tiago Torres   +2 more
doaj   +1 more source

Lebrikizumab for adolescent atopic dermatitis: 24-week real-world outcomes from the Czech BIOREP registry [PDF]

JAAD International
Filip Rob, MD, PhD, Blanka Pinková, MD, PhD, Petra Gkalpakioti, MD, Jiřina Bartoňová, MD, Jiří Horažďovský, MD, PhD, Jan Říčař, MD, PhD, Jana Třešňák Hercogová, MD, PhD, Kristýna Sokolová, MD   +7 more
doaj   +2 more sources

Lebrikizumab for atopic dermatitis. [PDF]

Aust Prescr
europepmc   +5 more sources

Lebrikizumab for the Treatment of Moderate-to-Severe Atopic Dermatitis

American Journal of Clinical Dermatology, 2023
Atopic dermatitis (AD) is a common, heterogeneous, inflammatory skin disorder characterized by chronic or relapsing eczematous lesions with intense pruritus and discomfort. Affected patients often experience significant impairment in their quality of life, and the treatment of moderate-to-severe AD forms remains challenging.
Diana Bernardo, Thomas Bieber, Tiago Torres   +2 more
openaire   +2 more sources

Docking analysis and the possibility of prediction efficacy for an anti-IL-13 biopharmaceutical treatment with tralokinumab and lebrikizumab for bronchial asthma. [PDF]

PLoS ONE, 2017
Interleukin-13 (IL-13) is associated with allergic airway inflammation and airway remodeling. Our group found a variant with a single nucleotide polymorphism in the IL13 gene at position +2044G>A (rs20541) that was expected to result in the non ...
Yutaka Nakamura, Aki Sugano, Mika Ohta, Yutaka Takaoka   +3 more
doaj   +1 more source

Phase 2 trial to assess lebrikizumab in patients with idiopathic pulmonary fibrosis

, 2021
This phase 2, randomised, double-blind, placebo-controlled trial evaluated the efficacy and safety of lebrikizumab, an interleukin (IL)-13 monoclonal antibody, alone or with background pirfenidone therapy, in patients with idiopathic pulmonary fibrosis ...
Scholand, Mary Beth, Glassberg, Marilyn K, Ogura, Takashi, Olsson, Julie, Swigris, Jeffrey J, Belloni, Paula, Howard, Monet, Maher, Toby M, Costabel, Ulrich, Kondoh, Yasuhiro, Neighbors, Margaret, Kardatzke, David   +11 more
core   +1 more source

Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials [PDF]

, 2023
BACKGROUND: Lebrikizumab is a novel, high-affinity monoclonal antibody that selectively binds to interleukin (IL)-13. OBJECTIVES: To evaluate the efficacy and safety of lebrikizumab monotherapy in adolescent and adult patients with moderate-to-severe ...
Morgan-Cox, MaryAnn, David Rosmarin, Blauvelt, Andrew, Morgan-Cox, Mary Ann, Pierce, Evangeline J., Bieber, Thomas, Rosmarin, David, Simpson, Eric L., Serra-Baldrich, E, Elmaraghy, Hany, Natalie, Chitra R, Guttman-Yassky, Emma, Serra-Baldrich, Esther, Garcia Gil, Esther, Thyssen, Jacob Pontoppidan, Simpson, Eric, Silverberg, Jonathan, Jonathan I Silverberg, Zhuqing Liu, Pierce, Evangeline, Eric Simpson, Andrew Blauvelt, Liu, Zhuqing, Chitra R Natalie, Silverberg, Jonathan I, Esther Serra-Baldrich, Thyssen, Jacob P, Natalie, Chitra R., Thomas Bieber, Hany Elmaraghy, Eric Meskimen, Evangeline Pierce, Rosmarin, David M., Xu, Chenjia, Jacob P Thyssen, Meskimen, Eric, Emma Guttman-Yassky, Chenjia Xu, MaryAnn Morgan-Cox, Esther Garcia Gil, García-Gil, Esther, Universitat Autònoma de Barcelona   +41 more
core   +1 more source

The efficacy and safety of lebrikizumab monotherapy for the management of moderate-to-severe atopic dermatitis: A systematic review and meta-analysis

Frontiers in Medicine, 2023
BackgroundAtopic dermatitis (AD) is a chronically relapsing disease. Few biologics are approved for moderate-to-severe AD, and novel interventions are emerging.
Bader Bashrahil, Bader Bashrahil, Ziyad Alzahrani, Ziyad Alzahrani, Sahal Samarkandy, Sahal Samarkandy, Abdullah Aman, Abdulhadi Jfri, Abdulhadi Jfri, Abdulhadi Jfri   +9 more
doaj   +1 more source

Raising the bar of efficacy in Atopic Dermatitis: deep response in week 16 responders treated with lebrikizumab over 2 years

Journal of Dermatological Treatment
Background Lebrikizumab, a high-affinity monoclonal antibody targeting interleukin-13, effectively treats moderate-to-severe atopic dermatitis (AD).Methods Lebrikizumab-treated patients in ADvocate1&2 achieving per-protocol response—IGA (0,1) or EASI 75 ...
Eric Simpson, Tilo Biedermann, Leon Kircik, Raj Chovatiya, Ignasi Figueras, Gaia Gallo, Marta Casillas, Yuxin Ding, Chenjia Xu, Chaoran Hu, Evangeline Pierce, Helena Agell, Christian Vestergaard   +12 more
doaj   +1 more source

The efficacy and safety of IL-13 inhibitors in atopic dermatitis: A systematic review and meta-analysis

Frontiers in Immunology, 2022
BackgroundSeveral clinical trials have evaluated the efficacy and safety of interleukin-13 (IL-13) with lebrikizumab and tralokinumab in patients with moderate to severe atopic dermatitis (AD).
Yan Zhang, Yan Zhang, Yan Zhang, Danrong Jing, Danrong Jing, Jun Cheng, Xiang Chen, Xiang Chen, Minxue Shen, Minxue Shen, Hong Liu, Hong Liu   +11 more
doaj   +1 more source